Research ArticleArticle
CYP3A Specifically Catalyzes 1β-Hydroxylation of Deoxycholic Acid: Characterization and Enzymatic Synthesis of a Potential Novel Urinary Biomarker for CYP3A Activity
Martin A. Hayes, Xue-Qing Li, Gunnar Grönberg, Ulf Diczfalusy and Tommy B. Andersson
Drug Metabolism and Disposition September 2016, 44 (9) 1480-1489; DOI: https://doi.org/10.1124/dmd.116.070805
Martin A. Hayes
Cardiovascular and Metabolic Diseases, Drug Metabolism and Pharmacokinetics (M.A.H., X.-Q.L., T.B.A.) and Respiratory, Inflammation and Autoimmune Disease, Medicinal Chemistry (G.G.), Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Mölndal, Sweden; Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (U.D.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (T.B.A.)
Xue-Qing Li
Cardiovascular and Metabolic Diseases, Drug Metabolism and Pharmacokinetics (M.A.H., X.-Q.L., T.B.A.) and Respiratory, Inflammation and Autoimmune Disease, Medicinal Chemistry (G.G.), Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Mölndal, Sweden; Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (U.D.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (T.B.A.)
Gunnar Grönberg
Cardiovascular and Metabolic Diseases, Drug Metabolism and Pharmacokinetics (M.A.H., X.-Q.L., T.B.A.) and Respiratory, Inflammation and Autoimmune Disease, Medicinal Chemistry (G.G.), Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Mölndal, Sweden; Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (U.D.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (T.B.A.)
Ulf Diczfalusy
Cardiovascular and Metabolic Diseases, Drug Metabolism and Pharmacokinetics (M.A.H., X.-Q.L., T.B.A.) and Respiratory, Inflammation and Autoimmune Disease, Medicinal Chemistry (G.G.), Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Mölndal, Sweden; Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (U.D.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (T.B.A.)
Tommy B. Andersson
Cardiovascular and Metabolic Diseases, Drug Metabolism and Pharmacokinetics (M.A.H., X.-Q.L., T.B.A.) and Respiratory, Inflammation and Autoimmune Disease, Medicinal Chemistry (G.G.), Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Mölndal, Sweden; Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (U.D.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (T.B.A.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
1β-OH-DCA as a Biomarker for CYP3A Activity
Martin A. Hayes, Xue-Qing Li, Gunnar Grönberg, Ulf Diczfalusy and Tommy B. Andersson
Drug Metabolism and Disposition September 1, 2016, 44 (9) 1480-1489; DOI: https://doi.org/10.1124/dmd.116.070805
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement